The Effect of Medications on Thyroid Function Tests

Medical Clinics of North America

Volumn 96, Issue 2, 2012, Pages 283-295

  Kundra, Priya ^a,b   Burman, Kenneth D ^a,b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Euthyroid state; Hormone; Medication; Thyroid function

Indexed keywords

ALBUMIN; ALEMTUZUMAB; ALPHA INTERFERON; AMIODARONE; BEXAROTENE; CELL NUCLEUS RECEPTOR; DEXAMETHASONE; DOPAMINE; GLUCOCORTICOID; GLUCURONIDE; HYDROCORTISONE; IMATINIB; IODIDE; LIOTHYRONINE; LIOTHYRONINE RECEPTOR; LITHIUM; OCTREOTIDE; PREALBUMIN; PREDNISONE; PROPYLTHIOURACIL; SULFATE; SUNITINIB; THIAMAZOLE; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN; THYROXINE; THYROXINE BINDING GLOBULIN; THYROXINE DEIODINASE; UNINDEXED DRUG;

AUTOIMMUNE THYROIDITIS; BILE; BILE FLOW; DEIODINATION; DRUG ABSORPTION; DRUG EFFECT; DRUG INDUCED DISEASE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GOITER; GRAVES DISEASE; HASHIMOTO DISEASE; HORMONE RELEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SULFATION; T CELL LYMPHOMA; THYROID CELL; THYROID FUNCTION TEST; THYROID HORMONE METABOLISM; THYROID HORMONE RELEASE; THYROID HORMONE SYNTHESIS; THYROIDITIS;

ADRENAL CORTEX HORMONES; ANTI-ARRHYTHMIA AGENTS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; HORMONE REPLACEMENT THERAPY; HUMANS; PRESCRIPTION DRUGS; RADIOISOTOPES; RISK FACTORS; THYROID DISEASES; THYROID FUNCTION TESTS; THYROID GLAND; VASODILATOR AGENTS;

EID: 84858775227     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.02.001     Document Type: Review

References (49)

1. Brabant K., Prank C., Hoang-Vu R.D., et al. Hypothalamic regulation of pulsatile thyrotropin secretion. J Clin Endocrinol Metab 1991, 72(1):145-150.
2. Agner T., Hagen C., Anderson A., et al. Increased dopaminergic activity inhibits basal and metoclopramide-stimulated prolactin and thyrotropin secretion. J Clin Endocrinol Metab 1986, 62(4):778-782.
3. Brabant G., Brabant U., Ranft K., et al. Circadian and pulsatile thyrotropin secretion in euthyroid man under the influence of thyroid hormone and glucocorticoid administration. J Clin Endocrinol Metab 1987, 65(1):83-88.
4. Williams T., Kelijman M., Crelin W., et al. Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man. J Clin Endocrinol Metab 1988, 66(1):39-45.
5. Sherman S.I. Etiology, diagnosis and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T cell lymphoma. Clin Lymphoma 2003, 3(4):249-252.
6. Smit J.W., Stokkel M.P., Pereira A.M., et al. Bexarotene induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. J Clin Endocrinol Metab 2007, 92(7):2496-2499.
7. Braverman L. Iodine induced thyroid disease. 3rd thyroid symposium, AMA.
8. Batcher E.L., Tang X.C., Singh B.N., SAFE-T Investigators, et al. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med 2007, 120(10):880-885.
9. Norman M.F., Lavin T.N. Antagonism of thyroid hormone action by amiodarone in rat pituitary tumor cells. J Clin Invest 1989, 83:306-313.
10. Basaria S., Cooper D.S. Amiodarone and the thyroid. Am J Med 2005, 118:706-714.
11. +. Endocrinology 1971, 88:1385-1388.
12. Lazarus J.H., Richards A.R., Addison G.M., et al. Treatment of thyrotoxicosis with lithium carbonate. Lancet 1974, 2:1160.
13. Burman K.D., Dimond R.C., Earll J.M., et al. Wartofsky sensitivity to lithium in treated Grave's disease: effects on serum T4, T3 and reverse T3. J Clin Endocrinol Metab 1976, 43(3):606-613.
14. Carella C., Mazziotti G., Amato G., et al. Interferon α related thyroid disease: pathophysiologic, epidemiologic, and clinical aspects. J Clin Endocrinol Metab 2004, 89(8):3656-3661.
15. Koh L.K., Greenspan F.S., Yeo P.P. Interferon α induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997, 7:891-896.
16. Carella C., Mazziotti G., Morisco F., et al. The addition if ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002, 146:743-749.
17. CAMMS223 Trial Investigators, Coles A.J., Compston D.A., et al. Alemtuzumab vs. interferon Beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801.
18. Gillard P., Huurman V., Van der Auwera B., et al. Graves' hyperthyroidism after stopping immune suppressive therapy in type I diabetic islet cell recipients with pretransplant TPO-autoantibodies. Diabetes Care 2009, 32:1-8.
19. Mandel S.J., Larsen P.R., Seely E.W., et al. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 1990, 323:91-96.
20. Alexander E.K. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med 2004, 351(3):241-249.
21. Arafah B.M. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001, 344:1743-1749.
22. Surks M.I., Sievert R. Drugs and thyroid function. N Engl J Med 1995, 333:1688-1694.
23. English T., Ruxton D., Eastman C. Abnormalities in thyroid function associated with chronic therapy with methadone. Clin Chem 1988, 34/11:2202-2204.
24. Deyssig R., Weissel M. Ingestion of androgenic-anabolic steroids induces mild thyroidal impairment in male body builders. J Clin Endocrinol Metab 1993, 76(4):1069-1071.
25. Wang R., Nelson J.C., Wilcox R.B. Salsalate and salicylate binding to and their displacement of thyroxine from thyroxine-binding globulin, transthyrin, and albumin. Thyroid 1999, 9(4):359-364.
26. Samuels M.H., Pillote K., Asher D., et al. Variable effects of nonsteroidal anti-inflammatory agents on thyroid test results. J Clin Endocrinol Metab 2003, 88(12):5710.
27. Jain R., Uy H.L. Increase in serum free thyrosine levels related to intravenous heparin treatment. Ann Intern Med 1996, 124(1 Pt 1):74-75.
28. Jaume J.C., Mendel C.M., Frost P.H., et al. Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum-free thyroxine concentration as measured by equilibrium dialysis. Thyroid 1996, 6:79.
29. Oppenheimer J.H., Bernstein G., Surks M.I. Increased thyroxine turnover and thyroidal function after stimulation of hepatocellular binding of thyroxine by phenobarbital. J Clin Invest 1968, 47:1399.
30. Isley W.L. Effect of rifampin therapy on thyroid function tests in a hypothyroid patient on replacement l-thyroxine. Ann Intern Med 1987, 107:517.
31. Surks M.I., DeFesi C.R. Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamezipine. JAMA 1996, 275:1495-1498.
32. Hays M.T. Thyroid hormone and the gut. Endocr Res 1988, 14(2-3):203-224.
33. Harmon S.M., Siefert C.F. Levothyroxine-cholestyramine interaction reemphasized. Ann Intern Med 1991, 115:658.
34. Singh N., Singh P.N., Hershman J.M. Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000, 283:2822.
35. Sherman S.I., Tielens E.T., Ladenson P.W. Sucralfate causes malabsorption of l-thyroxine. Am J Med 1994, 96(6):531-535.
36. Campbell N.R., Hasinoff B.B., Stalts H., et al. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med 1992, 117(12):1010-1013.
37. Sperber A.D., Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch Intern Med 1992, 152(1):183-184.
38. Centanni M., Gargano L., Canettieri G., et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006, 354:1787.
39. Benvenga S., Bartolone L., Pappalardo M.A., et al. Altered intestinal absorption of l-thyroxine caused by coffee. Thyroid 2008, 18(3):293-301.
40. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007, 25(7):884-896.
41. Desai J., Yassa L., Marqusee E., et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal tumors. Ann Intern Med 2006, 145:660-664.
42. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007, 99:81-83.
43. Grossmann M., Premaratne E., Desai J., et al. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol 2008, 69(4):669-672.
44. Mannavola D., Coco P., Vannachi G., et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007, 92(9):3531-3534.
45. Salem A.K., Fenton M.S., Marion K.M., et al. Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 2008, 18(6):631-635.
46. Wong E., Rosen L.S., Mulay M., et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007, 17(4):351-355.
47. Alexandrescu D.T., Popoveniuc G., Farzanmehr H., et al. Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 2008, 18(7):809-812.
48. Torino F., Corsello S., Longo R., et al. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?. Thyroid 2009, 19(5):539-540.
49. De Groot J.W., Zonnenberg B.A., Plukker J.T., et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005, 78:433-438.